United Therapeutics (NASDAQ:UTHR) Director Christopher Patusky Sells 1,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Patusky sold 1,000 shares of United Therapeutics stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $495.95, for a total transaction of $495,950.00. Following the completion of the sale, the director directly owned 1,490 shares in the company, valued at $738,965.50. This trade represents a 40.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

United Therapeutics Stock Performance

NASDAQ UTHR traded down $0.30 on Tuesday, hitting $500.00. 483,805 shares of the stock traded hands, compared to its average volume of 578,260. The business’s fifty day moving average is $458.75 and its two-hundred day moving average is $376.11. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $502.77. The firm has a market capitalization of $21.53 billion, a price-to-earnings ratio of 18.95, a PEG ratio of 4.90 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.39 EPS. Analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. HighTower Advisors LLC raised its holdings in shares of United Therapeutics by 8.1% in the 1st quarter. HighTower Advisors LLC now owns 20,362 shares of the biotechnology company’s stock valued at $6,277,000 after acquiring an additional 1,530 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of United Therapeutics by 0.7% during the first quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock worth $192,571,000 after purchasing an additional 4,145 shares in the last quarter. American Century Companies Inc. increased its position in shares of United Therapeutics by 0.4% in the first quarter. American Century Companies Inc. now owns 38,320 shares of the biotechnology company’s stock worth $11,813,000 after purchasing an additional 168 shares during the last quarter. Cresset Asset Management LLC raised its stake in United Therapeutics by 1.3% in the first quarter. Cresset Asset Management LLC now owns 8,687 shares of the biotechnology company’s stock valued at $2,678,000 after purchasing an additional 108 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its position in United Therapeutics by 7.3% during the first quarter. Raymond James Financial Inc. now owns 55,545 shares of the biotechnology company’s stock valued at $17,123,000 after purchasing an additional 3,801 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on UTHR. Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. Oppenheimer upped their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Royal Bank Of Canada lifted their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Finally, Wells Fargo & Company increased their target price on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.